These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 6138267)

  • 1. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.
    Koch SW; Koe BK; Bacopoulos NG
    Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of intranigral administration of a dopamine analogue, (+/-)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(+/-)-3-PPP], on nigrostriatal dopamine neurones.
    Kelly E; Jenner P; Marsden CD
    Neurosci Lett; 1985 May; 56(1):57-62. PubMed ID: 4011049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.
    Clark D; Hjorth S; Carlsson A
    Eur J Pharmacol; 1984 Oct; 106(1):185-9. PubMed ID: 6099268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D; Salah RS; Galloway MP
    Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.
    Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC
    Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Psychopharmacology (Berl); 1983; 81(3):199-207. PubMed ID: 6139838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A
    Psychopharmacology (Berl); 1983; 81(2):89-99. PubMed ID: 6415751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
    Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
    Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine enantiomers' effects on dopamine metabolism: receptor and non-receptor related actions.
    Saller CF; Salama AI
    Eur J Pharmacol; 1986 Feb; 121(2):181-8. PubMed ID: 3699091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of apomorphine and (+/-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine, injected into the striatum, on the caudate spindle in the rat.
    Hashimoto S; Okuyama S; Aihara H
    Neuropharmacology; 1987 Jul; 26(7A):663-7. PubMed ID: 2888038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effect of the racemic mixture and the (-)enantiomer of N-n-propyl-3-(3-hydroxyphenyl)-piperidine (3-PPP) on postsynaptic dopamine receptors and on a presynaptic dopamine autoreceptor.
    Markstein R; Lahaye D
    J Neural Transm; 1983; 58(1-2):43-53. PubMed ID: 6317801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
    Booth RG; Baldessarini RJ; Kula NS; Gao Y; Zong R; Neumeyer JL
    Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system.
    Clark D; Engberg G; Pileblad E; Svensson TH; Carlsson A; Freeman AS; Bunney BS
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):344-54. PubMed ID: 4033804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation.
    Oberlander C; Boissier JR
    J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic antidepressant administration fails to attenuate apomorphine-induced decreases in rat striatal dopamine metabolites.
    Diggory GL; Buckett WR
    Eur J Pharmacol; 1984 Oct; 105(3-4):257-63. PubMed ID: 6510470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation.
    Hjorth S; Clark D; Carlsson A
    Eur J Pharmacol; 1988 Aug; 152(3):207-15. PubMed ID: 3146512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
    Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.